第1章 產品概要

第2章 SWOT分析

分析師的觀點

第3章 法規的里程碑

核准

研究開發

臨床試驗資訊

安全性和有效性

產品開發活動

第4章 市場評估

主要7個國家市場分析

美國

歐洲(英國·德國·法國·義大利·西班牙)

日本

主要調查結果

第5章 競爭情形

第6章 新治療方法

第7章 附錄

目錄

Product Code: DIDM0029

Overview

"Xifaxan (rifaximin) - Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Xifaxan (rifaximin) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Scope of the report

The report provides insights into:

A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.

Elaborated details on regulatory milestones and other development activities have been provided in this report.

The report also highlights the drug marketed details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around Xifaxan (rifaximin).

Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.

The report also features the SWOT analysis with analyst insights and key findings of Xifaxan (rifaximin).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Xifaxan (rifaximin) Analytical Perspective by DelveInsight

In-depth Xifaxan (rifaximin) Market Assessment

This report provides a detailed market assessment of Xifaxan (rifaximin) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

In the coming years, the market scenario for Xifaxan (rifaximin) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence Xifaxan (rifaximin) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Other approved products for the disease are giving market competition to Xifaxan (rifaximin) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Xifaxan (rifaximin).

Our in-depth analysis of the sales data of Xifaxan (rifaximin) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Xifaxan (rifaximin) in the market.

Key Questions

What is the prescribed dosage and strengths of Xifaxan (rifaximin) are available in the market?

What are the common adverse reactions or side effects of Xifaxan (rifaximin)?

What is the product type, route of administration and mechanism of action of Xifaxan (rifaximin)?

What are the chemical specifications of Xifaxan (rifaximin)?

How are the clinical trials diversified on the basis of the trial status?

What is the history of Xifaxan (rifaximin), and what is its future?

What are the marketed details of Xifaxan (rifaximin) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

How many patents have been granted to Xifaxan (rifaximin) and when these patents will get expire?

What are the pros (benefits) and cons (disadvantages) of Xifaxan (rifaximin)?

In which countries Xifaxan (rifaximin) got approval and when it gets launched?

What are the clinical trials are currently ongoing for Xifaxan (rifaximin)?

How the safety and efficacy results determined the approval of Xifaxan (rifaximin)?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Xifaxan (rifaximin) development?

What are the key designations that have been granted to Xifaxan (rifaximin)?

What is the historical and forecasted market scenario of Xifaxan (rifaximin)?

How is the market trend of Xifaxan (rifaximin) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?

What are the other approved products available and how these are giving competition to Xifaxan (rifaximin)?

Which are the late-stage emerging therapies under development for the treatment of the indicated condition?